Search filters

Filters
Clear All

Phase

  • 33
  • 94
  • 1
  • 80
  • 37
  • 1
  • 114
  • 383
  • 176
  • 13
  • 19
  • 351
  • 378
  • 5
  • 1
  • 382

Found 383 Neoplasms trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
Phase 1
Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints) Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints) Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints)
 A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy
18 years - 99 years
Male
Phase 1
Interventional
Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06873600 administered as a single agent and then in combination with endocrine therapy. The study contains two parts, a Part 1 single agent dose escalation and combination endocrine therapy dose finding component and a Part …
99 years or below
All genders
This is a small scale investigational study to compare different fluorescent camera imaging systems against the current standard (Visionsense VS3 Iridium system) for patients with Ovarian cancer. The VS3 is and FDA approved device currently in phase 3 clinical trials at the University of Pennsylvania and other institutions in combination …
99 years or below
All genders
The purpose of this study is to see if sacituzumab govitecan can improve lifespans of patients with advanced TNBC and their tumor does not grow or spread when compared to chemotherapy (paclitaxel, or nab-paclitaxel, or the combination of gemcitabine and carboplatin), a commonly used treatment for previously untreated advanced TNBC.
 ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA
18 years - 99 years
All genders
Purpose is to determine if cemiplimab (given as infusion in the vein) will prevent cutaneous squamous cell cancer from returning after surgery and radiation. Subjects at least 18 years of age who have had surgery and radiation therapy for cutaneous squamous cell cancer, and there is a risk that this …
99 years or below
All genders
Phase 1
This is a Phase 1 study that will evaluate the effectiveness of TPST-1120. Subjects may receive TPST-1120 alone or in combination with nivolumab. Subjects eligible to participate are those with advanced solid tumors.
 A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients with Newly Diagnosed or Recurrent Meningiomas
18 years - 99 years
All genders
Phase 3
This study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real time detection and visualization of meningiomas during tumor resection surgery. Potential patients who sign informed consent will be screened for eligibility before receiving an oral solution of Gleolan 3 hours prior to …
 Combination Ipatasertib and Atezolizumab to Prevent Recurrence in Triple Negative Breast Cancer
18 years - 99 years
All genders
Phase 2
The purpose of this study is to determine if a combination of two drugs, Ipatasertib and Atezolizumab, works as a treatment for residual cancer in breast or lymph nodes and have circulating tumor DNA in blood. Eligible subjects will be those with triple negative breast cancer.
 UPCC 24116: A Phase II Pilot Trial of Hydroxychloroquine  Everolimus or the Combination for Prevention of Recurrent Breast Cancer
99 years or below
All genders
Phase 2
The main purpose of this study is to: 1) determine the feasibility of giving hydroxychloroquine, everolimus or the combination to people with disseminated tumor cells detected in their bone marrow. 2) determine how tolerable these drugs are in people who have completed treatment for breast cancer. 3) determine how well …
99 years or below
All genders
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
221 - 230 of 383